5月12日午盘,恒瑞医药突然放出一枚深水炸弹:和全球制药巨头百时美施贵宝(BMS)达成了重磅合作! 这笔买卖到底有多大?潜在总交易额高达152亿美元!BMS先支付9.5亿美元首付和近期付款,后面只要药物研发能顺利推下去,恒瑞还能拿到上百亿的里程碑付款,甚至未来的销售分成! 这次合作涉及13款早期创新药,主攻肿瘤、血液和免疫疾病。有意思的是,恒瑞不仅保留了大中华区的权益,还要全权负责早期的临床...
Source Link5月12日午盘,恒瑞医药突然放出一枚深水炸弹:和全球制药巨头百时美施贵宝(BMS)达成了重磅合作! 这笔买卖到底有多大?潜在总交易额高达152亿美元!BMS先支付9.5亿美元首付和近期付款,后面只要药物研发能顺利推下去,恒瑞还能拿到上百亿的里程碑付款,甚至未来的销售分成! 这次合作涉及13款早期创新药,主攻肿瘤、血液和免疫疾病。有意思的是,恒瑞不仅保留了大中华区的权益,还要全权负责早期的临床...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.